Abstract
The rapid growth of the global HIV/AIDS epidemic makes it a high priority to develop an effective vaccine. Since a live attenuated or inactivated HIV vaccine is not likely to be approved for clinical application due to safety concerns, HIV virus like particles (VLPs) offer an attractive alternative because they are considered safer since they lack viral genome. We got a stable eukaryotic cell line by G418 resistance selection, engineered to express the HIV-1 structure protein Gag and Env efficiently and stably. We confirmed the presence of Gag and Env proteins in the cell culture supernatant and that they could self-assemble into VLPs. These VLPs were found to be able to elicit specific humoral and cellular immune response after immunization without any adjuvant.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Gamble L J, Matthews Q L. Current progress in the development of a prophylactic vaccine for HIV-1. Drug Des Devel Ther, 2010, 5: 9–26
Fenouillet E, Barbouche R, Jones I M. Cell entry by enveloped viruses: redox considerations for HIV and SARS-coronavirus. Antioxid Redox Sign, 2007, 9: 1009–1034
Devico A, Fouts T, Lewis G K, et al. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci USA, 2007, 104: 17477–17482
Doms R W, Moore J P. HIV-1 membrane fusion: targets of opportunity. J Cell Biol, 2000, 151: F9–14
Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science, 1998, 280: 1884–1888
Tagliamonte M, Tornesello M L, Buonaguro F M, et al. Conformational HIV-1 envelope on particulate structures: a tool for chemokine coreceptor binding studies. J Transl Med, 2011, 9: S1
Buonaguro L, Buonaguro F M, Tornesello M L, et al. High efficient production of Pr55(gag) virus-like particles expressing multiple HIV-1 epitopes, including a gp120 protein derived from an Ugandan HIV-1 isolate of subtype A. Antiviral Res, 2001, 49: 35–47
Gheysen D, Jacobs E, De Foresta F, et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell, 1989, 59: 103–112
Yamshchikov G V, Ritter G D, Vey M, et al. Assembly of SIV virus-like particles containing envelope proteins using a baculovirus expression system. Virology, 1995, 214: 50–58
Wagner R, Deml L, Fliessbach H, et al. Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles. Virology, 1994, 200: 162–175
Wang B Z, Liu W, Kang S M, et al. Incorporation of high levels of chimeric human immunodeficiency virus envelope glycoproteins into virus-like particles. J Virol, 2007, 81: 10869–10878
Crooks E T, Moore P L, Franti M, et al. A comparative immunogenicity study of HIV-1 virus-like particles bearing various forms of envelope proteins, particles bearing no envelope and soluble monomeric gp120. Virology, 2007, 366: 245–262
Yao Q, Bu Z, Vzorov A, et al. Virus-like particle and DNA-based candidate AIDS vaccines. Vaccine, 2003, 21: 638–643
Bachmann M F, Lutz M B, Layton G T, et al. Dendritic cells process exogenous viral proteins and virus-like particles for class I presentation to CD8+ cytotoxic T lymphocytes. Eur J Immunol, 1996, 26: 2595–2600
Deml L, Kratochwil G, Osterrieder N, et al. Increased incorporation of chimeric human immunodeficiency virus type 1 gp120 proteins into Pr55gag virus-like particles by an Epstein-Barr virus gp220/350-derived transmembrane domain. Virology, 1997, 235: 10–25
Reimann J, Schirmbeck R. Alternative pathways for processing exogenous and endogenous antigens that can generate peptides for MHC class I-restricted presentation. Immunol Rev, 1999, 172: 131–152
Visciano M L, Diomede L, Tagliamonte M, et al. Generation of HIV-1 virus-like particles expressing different HIV-1 glycoproteins. Vaccine, 2011, in press
Speth C, Bredl S, Hagleitner M, et al. Human immunodeficiency virus type-1 (HIV-1) Pr55gag virus-like particles are potent activators of human monocytes. Virology, 2008, 382: 46–58
Deml L, Speth C, Dierich M P, et al. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol Immunol, 2005, 42: 259–277
Doan L X, Li M, Chen C, et al. Virus-like particles as HIV-1 vaccines. Rev Med Virol, 2005, 15: 75–88
Lebedev L R, Karpenko L I, Poryvaeva V A, et al. Design of virus-like particles, exposing HIV-1 epitopes. Mol Biol (Mosk), 2000, 34: 480–485
Young K R, Mcburney S P, Karkhanis L U, et al. Virus-like particles: designing an effective AIDS vaccine. Methods, 2006, 40: 98–117
Jiang C. Enhancement of cytokine to HIV-1 vaccine DNA prime/MVA boost regime. Dissertation for Doctoral Degree. Changchun: Jilin University, 2005
Seder R A, Hill A V. Vaccines against intracellular infections requiring cellular immunity. Nature, 2000, 406: 793–798
Wagner R, Fliessbach H, Wanner G, et al. Studies on processing, particle formation, and immunogenicity of the HIV-1 gag gene product: a possible component of a HIV vaccine. Arch Virol, 1992, 127: 117–137
Sakuragi S, Goto T, Sano K, et al. HIV type 1 Gag virus-like particle budding from spheroplasts of Saccharomyces cerevisiae. Proc Natl Acad Sci USA, 2002, 99: 7956–7961
Tsunetsugu-Yokota Y, Morikawa Y, Isogai M, et al. Yeast-derived human immunodeficiency virus type 1 p55(gag) virus-like particles activate dendritic cells (DCs) and induce perforin expression in Gag-specific CD8+ T cells by cross-presentation of DCs. J Virol, 2003, 77: 10250–10259
Author information
Authors and Affiliations
Corresponding authors
Additional information
This article is published with open access at Springerlink.com
Rights and permissions
Open Access This is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
About this article
Cite this article
Zhang, X., Wang, X., Zhao, D. et al. Design and immunogenicity assessment of HIV-1 virus-like particles as a candidate vaccine. Sci. China Life Sci. 54, 1042–1047 (2011). https://doi.org/10.1007/s11427-011-4244-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-011-4244-0